Use of the composition

Abstract

The present application relates to the use of a composition, for example the use of a composition in the manufacture of a product for improving eczema, wherein the composition comprises medium-long chain fatty acid triglycerides and osteopontin, wherein the mass ratio of the medium-long chain fatty acid triglycerides to the osteopontin is 1:1 to 100:1. The composition has a synergistic effect in improving allergy and / or eczema. The present application also relates to a product comprising the composition and the use of the composition in the manufacture of a product for improving allergy and / or eczema.

Description

Technical Field

[0001] This application relates to the use of the composition. Background Technology

[0002] Eczema is an inflammation of the epidermis and superficial dermis caused by a variety of internal and external factors. In the acute phase, the skin lesions are mainly papulovesicles with a tendency to ooze, while in the chronic phase, lichenification is the main feature, and it is prone to recurrence. In recent years, the global incidence of eczema has been on the rise, affecting about 2.0% of adults and 4.0% of children. The pathogenesis of eczema is closely related to the interaction between many factors such as genetic background, environmental factors, skin barrier dysfunction, microbial imbalance, immune dysregulation and skin inflammation (Zhang Aili, Xu Na, Wang Juan, et al. Peripheral serum levels of 25-hydroxyvitamin D, IL-4, IL-10 and IL-17 in adult eczema and their clinical significance [J]. Guizhou Medical Journal, 2026, 50(03): 467-473).

[0003] In view of the above problems, it is of great significance to develop ways to effectively improve eczema. Summary of the Invention

[0004] This application is made in view of the aforementioned problems existing in the prior art.

[0005] In a first aspect, this application relates to the use of a composition in the preparation of a product for improving eczema, wherein the composition comprises a medium- and long-chain triacylcerol (MLCT) and osteopontin (OPN), wherein the mass ratio of MLCT to OPN is from 1:1 to 100:1.

[0006] In some implementations, the mass ratio of the MLCT to the OPN is from 5:1 to 100:1.

[0007] In some implementations, the mass ratio of the MLCT to the OPN is from 1:1 to 50:1.

[0008] In some embodiments, the mass ratio of the MLCT to the OPN is 5:1 to 50:1.

[0009] In some embodiments, the eczema is allergic eczema.

[0010] In some embodiments, the improvement of eczema includes one or more of relieving itching and reducing trypsin levels.

[0011] The beneficial effects of this application include: when MLCT and OPN are used in combination at a specific mass ratio, they exhibit a synergistic effect in improving allergies and / or eczema, particularly in relieving itching and reducing trypsin levels. The combined effect is superior to the effect of using the same amount of MLCT alone or the same amount of OPN alone, and also superior to the sum of the effects of using the same amount of MLCT alone and the same amount of OPN alone. For example, when MLCT and OPN are used at a mass ratio of 1:1 to 100:1, the composition can synergistically relieve itching and / or reduce trypsin levels, thereby improving allergies and / or eczema. Preferably, when MLCT and OPN are used at a mass ratio of 5:1 to 100:1, or at a mass ratio of 1:1 to 50:1, the composition can synergistically relieve itching and / or reduce trypsin levels, thereby improving allergies and / or eczema. Attached Figure Description

[0012] To more clearly illustrate the technical solutions of this application, the accompanying drawings required for describing the embodiments will be briefly described below. It should be understood that these drawings are only for the purpose of facilitating a better understanding of this application by those skilled in the art, and are not intended to limit the scope of this application.

[0013] Figure 1 A typical graph showing the total movement distance of zebrafish after sample treatment is presented, where the black line represents the slow movement distance, the green line represents the medium movement distance, and the red line represents the fast movement distance. Detailed Implementation

[0014] To provide a clearer understanding of the technical features, objectives, and beneficial effects of this application, the technical solution of this application is described in detail below with reference to specific embodiments and accompanying drawings. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. Unless otherwise specifically defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed can and have been performed in a manner commonly known and understood by one of ordinary skill in the art.

[0015] In this application, unless otherwise specified, the temperature is room temperature (e.g., 25°C), the atmosphere is air, and the pressure is normal pressure (e.g., 1 atmosphere).

[0016] In this application, the term "medium-chain fatty acid" refers to fatty acids with 6 to 12 carbon atoms in their carbon chain, such as hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, and dodecanoic acid. The term "long-chain fatty acid" refers to fatty acids with 14 or more carbon atoms in their carbon chain, generally 14 to 30 carbon atoms, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. The terms "medium-chain fatty acid triglyceride" (MCT) and "long-chain fatty acid triglyceride" (LCT) refer to the esterification products of medium-chain fatty acids and long-chain fatty acids with glycerol, respectively. The term "medium- and long-chain fatty acid triglycerides" refers to triglycerides that contain both medium-chain fatty acid residues and long-chain fatty acid residues in their molecular structure.

[0017] This application relates to compositions comprising MLCT and OPN, products comprising the above compositions, the use of the above compositions in the preparation of products for improving allergies and / or eczema, and the use of the above compositions or products for non-therapeutic purposes for improving allergies and / or eczema. The application will be described in detail below.

[0018] Composition

[0019] A first aspect of this application provides a composition comprising medium- and long-chain triglycerides (MLCT) and osteopontin (OPN), wherein the mass ratio of MLCT to OPN is from 1:1 to 100:1.

[0020] As used in this article, "medium- and long-chain triglycerides" (MLCT) refers to triglycerides with one or two medium-chain fatty acids linked to the glycerol backbone, and the remainder being long-chain fatty acids. High doses of medium-chain triglycerides (MCT) can easily induce gastrointestinal discomfort, and long-term use carries the risk of ketoacidosis or ketoacidosis; while long-chain triglycerides (LCT) have lower absorption efficiency. Compared with LCT or MCT, natural or synthetic MLCT has unique composition, structure, and metabolic characteristics, and is therefore closely related to a variety of beneficial physiological functions. Early studies have shown that the fatty acid composition of MLCT is closer to that of breast milk, which helps in the digestion and absorption of fat, improves the utilization efficiency of fat-soluble nutrients, inhibits the accumulation of body fat, and can provide energy quickly and stably (Yuan Tinglan, Wei Wei, Ye Xingwang, et al. Research progress on medium- and long-chain triglycerides in breast milk [J]. Journal of Food and Biotechnology, 2022, 41(6):10). In addition, under the same total fatty acid composition, the differences in the molecular structure of triglycerides can significantly affect their biological functions. For example, mouse experiments have shown that, compared with mice fed a diet containing a physical mixture of LCT / MCT vegetable oils with the same fatty acid composition, mice fed a diet containing MLCT structured esters exhibited effects such as thermoregulation, inhibition of visceral fat accumulation, alteration of gut microbiota, and regulation of lipid metabolism (Yuan T, Cheng X, Shen L, Liu Z, Ye X, Yan Z, Wei W, Wang X. Novel Human Milk Fat Substitutes Based on Medium- and Long-Chain Triacylglycerol Regulate Thermogenesis, Lipid Metabolism, and Gut Microbiota Diversity in C57BL / 6J Mice. J Agric Food Chem. 2024 Mar 27;72(12):6213-6225). However, there are currently no reports on the correlation between MLCT and allergies or eczema.

[0021] As is known in the art, medium- and long-chain fatty acid triglycerides are produced by using edible vegetable oils and MCTs as raw materials, through transesterification by lipases, followed by processes such as distillation, decolorization, and deodorization.

[0022] This application does not have any particular requirements regarding the medium- and long-chain triglycerides used; medium- and long-chain triglycerides commonly used in the art can be used. Medium- and long-chain triglycerides can be used in pure form or in a non-pure form rich in medium- and long-chain triglycerides. For example, the medium- and long-chain triglycerides used in the compositions of this application can be medium- and long-chain triglycerides with a single composition (i.e., each molecular chain has the same long-chain fatty acid residues and the same medium-chain fatty acid residues), or a mixture of multiple medium- and long-chain triglycerides with two or more different compositions (i.e., each molecular chain has different long-chain fatty acid residues and / or different medium-chain fatty acid residues).

[0023] In some embodiments, the medium- and long-chain fatty acid triglycerides used in this application may contain C6-C6. 12 (e.g., C6, C7, C8, C9, C) 10 C 11 C 12 (or the range defined by either or both) fatty acid residues and C 14 ~C 30 (e.g., C) 14 C 15 C 16 C 17 C 18 C 19 C 20 C 21 C 22 C 23 C 24 C 25 C 26 C 27 C 28 C 29 C 30 (or the range defined by either C6-C6) fatty acid residues. In some examples, C6-C6... 12 Fatty acid residues can originate from one or more of the following: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, and lauric acid, etc. C 14 ~C 30 Fatty acid residues can be derived from one or more of the following: myristic acid, palmitic acid, heptadecanic acid, oleic acid, linoleic acid, stearic acid, nonadecanic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapatraenoic acid, docosahexaenoic acid, tricarboxylic acid, tetracarboxyenoic acid, docosapentaenoic acid, docosahexaenoic acid, arachidonic acid, etc. In some examples, C6~C... 12 The fatty acid residues may be derived from one or more of the following: hexanoic acid, caprylic acid, decanoic acid, and lauric acid. In some examples, C... 14 ~C 30Fatty acid residues may be derived from one or more of the following: myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.

[0024] In some embodiments, the medium- and long-chain fatty acid triglycerides used in this application have C6~C6... 12 Fatty acid residues and C 14 ~C 30 The unit weight ratio of fatty acid residues can be from 0.124 to 2.000. For example, in the medium- and long-chain fatty acid triglycerides used in this application, C6~C 12 Fatty acid residues and C 14 ~C 30 The unit weight ratio of fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or within the range defined by any two of these.

[0025] As used in this article, osteopontin (OPN) is a natural protein that is widely present in human body fluids, with the highest content found in breast milk. OPN derived from human milk and the milk of other mammals is called milk-derived osteopontin (abbreviated as lactopontin), and has been proven to have a positive effect on the immune maturation, intestinal health and nervous system development of infants and young children (Chinese Institute of Food Science and Technology, Wang Ou, Ruan Huijuan, et al. Scientific evidence of milk-derived osteopontin (2024 edition) [J]. Chinese Journal of Food Science, 2025, 25(1): 469-474). Recent research indicates that OPN is a key regulatory molecule in two types of allergic reactions: In immediate-type allergic asthma, OPN enhances sensitization and inhibits IL-4-related inflammatory responses dominated by the Th2 pathway, a role corroborated by elevated OPN expression during specific immunotherapy; while in Th1-mediated delayed-type allergies (such as allergic contact dermatitis), OPN secreted by effector T cells and keratinocytes promotes dendritic cell migration, upregulates IL-12 expression, amplifies the Th1-type allergic response, and drives disease progression (Frenzel DF, Weiss JM. Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol. 2011 Jan;7(1):93-109). Currently, there is no clear research demonstrating a relationship between oral osteopontin and eczema improvement.

[0026] In principle, there are no particular restrictions on the source of the OPN in this application. It can generally be obtained by extraction from animal milk or its products. In some preferred embodiments, such animal milk or its products can be cow milk, sheep milk, camel milk, horse milk or dairy products based on them (e.g., cheese), etc. More preferably, it can be extracted from cow milk, including bovine colostrum or regular bovine milk.

[0027] This application does not specifically limit the method for extracting OPN from the above-mentioned animal milk or its products. For example, multi-step chromatographic purification can be used, or OPN can be separated by free-flow isoelectric focusing electrophoresis.

[0028] Alternatively, OPN can also be obtained commercially, such as Lacprodan® OPN-10, OPN-05, or other similar commercially available products manufactured by Arla Foods Ingredients, Denmark.

[0029] In some embodiments, the mass ratio of MLCT to OPN in the compositions of this application is from 1:1 to 100:1. When MLCT and OPN are used in combination at mass ratios within the above range, the compositions of this application show a significant synergistic effect in improving allergies and / or eczema, particularly in relieving itching and / or reducing trypsin levels. As examples, the mass ratio of MLCT to OPN can be 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2.0:1, 2.2:1, 2.4:1, 2.5:1, 2.6:1, 2.8:1, 3.0:1, 3.3:1, 3.6:1, 4.0:1, 4.5:1, 5.0:1, 5.5:1, 6.0:1, 6.5:1, 7.0:1, 7.5:1, 8.0:1, 8.5:1, 9.0:1, 9.5:1, 10.0:1, 11:1, 12:1, 13:1, 1 4:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 22:1, 24:1, 28:1, 32:1, 34:1, 35:1, 36:1, 38:1, 40:1, 42:1, 44:1, 45:1, 46:1, 48:1, 50:1, 52:1, 55:1, 58:1, 60:1, 62:1, 65:1, 68:1, 70:1, 72:1, 75:1, 78:1, 80:1, 82:1, 85:1, 88:1, 90:1, 92:1, 95:1, 98:1 or 100:1, or within the range defined by any two of the above.

[0030] Preferably, the mass ratio of MLCT to OPN is 5:1 to 100:1. Alternatively, preferably, the mass ratio of MLCT to OPN is 1:1 to 50:1. When MLCT and OPN are used in combination at mass ratios within the above ranges, the synergistic effect of the composition of this application in improving allergies and / or eczema, particularly relieving itching and / or reducing trypsin levels, is more pronounced.

[0031] In some embodiments, the composition of this application may consist of MLCT and OPN, for example, MLCT and OPN in any mass ratio or mass ratio range described above.

[0032] product

[0033] A second aspect of this application provides a product comprising the composition described in the first aspect of this application.

[0034] In some embodiments, the product includes or is a pharmaceutical product.

[0035] In some embodiments, the product is a pharmaceutical product. This invention does not place particular requirements on the dosage form of the pharmaceutical product; commonly used pharmaceutical dosage forms in the art can be used. As examples, the pharmaceutical product of this invention can be a solid dosage form, such as powders, granules, tablets, capsules, drop pills, or pills; a semi-solid dosage form, such as ointments, creams, eye ointments, or gels; or a liquid dosage form, such as oral liquid preparations, such as syrups, mixtures, suspensions, or emulsions. Those skilled in the art will readily understand that, depending on the dosage form and application scenario, the pharmaceutical product may also include various pharmaceutically permissible excipients. Furthermore, the pharmaceutical product of this invention can be prepared using methods commonly employed in the art, which will not be elaborated upon here.

[0036] All descriptions of the composition above apply here and will not be repeated here.

[0037] In some embodiments, the composition according to the first aspect of this application may be added to a product as a beneficial ingredient.

[0038] In some embodiments, the MLCT content can be from 0.1% to 30.0% based on the dry basis weight of the product. As an example, the MLCT content can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, 1% based on the weight of the product. 2.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0% (dry basis mass), or within the range defined by any two of the above. Furthermore, in a further embodiment, the OPN content is calculated proportionally.

[0039] In other embodiments, the OPN content may be from 0.1% to 30.0% based on the dry basis weight of the product. As an example, the OPN content may be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11.0%, 11.5%, 12.0%, based on the weight of the product. 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0% by dry weight, or within the range defined by any two of the above.

[0040] use

[0041] The third aspect of this application provides the use of the composition according to the first aspect of this application in the preparation of products that improve allergies and / or eczema.

[0042] All descriptions of the composition above apply here and will not be repeated here.

[0043] In some implementations, there are no particular limitations on the subjects (recipients) who are improving allergies and / or eczema, and may include, for example, infants, toddlers, children, adolescents, adults, young adults, middle-aged people, and / or the elderly. As used herein, the term “infant” refers to a person aged from birth to 12 months; the term “toddler” refers to a person aged 1 to 3 years; the term “child” refers to a person aged 3 to 7 years; the term “adolescent” refers to a person aged 7 to 17 years; the term “adult” refers to a person aged 18 years or older; the term “young adult” refers to a person aged 18 to 40 years; the term “middle-aged person” refers to a person aged 41 to 65 years; and the term “elderly person” or “senior person” refers to a person aged 65 years or older.

[0044] In some embodiments, the method for improving allergies and / or eczema includes preventing allergies and / or eczema, or relieving one or more symptoms of allergies and / or eczema. For example, preventing allergies and / or eczema includes, for instance, preventing the occurrence or development of allergies and / or eczema; and, for example, relieving one or more symptoms of allergies and / or eczema includes, for instance, relieving or reducing itching, and / or reducing trypsin levels.

[0045] As described above, when MLCT and OPN are used in combination at a specific mass ratio (e.g., any mass ratio or range of mass ratios described above), the product used according to the fourth aspect of this application exhibits a synergistic effect in improving allergies and / or eczema, particularly in relieving itching and reducing trypsin levels.

[0046] In some embodiments, when the product used according to the fourth aspect of this application is used to improve allergies and / or eczema, particularly to relieve itching and reduce trypsin levels, the dosage may be such that the intake of MLCT is 2.25 g to 30 g per day, for example, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.25, 4.50, 4.75, 5.00, 5.25, 5.50, 5.75, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.25, 8.50, 8.75, 9.00, 9.25, 9.50, 9.75, 10.0, 10.5, 11.0, 11.5, 1 2.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 g, or within any two of the above ranges. Furthermore, in a further embodiment, the intake of the OPN is proportionally converted.

[0047] The fifth aspect of this application provides for the use of the composition according to the first aspect of this application or the product according to the second aspect of this application for non-therapeutic purposes to improve allergies and / or eczema.

[0048] In some embodiments, the non-therapeutic purpose refers to a non-medical therapeutic purpose (e.g., nutritional and / or health care purpose), such as for preparing a product for preventing allergies and / or eczema or for relieving one or more symptoms of allergies and / or eczema.

[0049] In some embodiments, the improvement of allergies and / or eczema may include relieving itching and / or reducing trypsin levels.

[0050] All descriptions above regarding the compositions described in the first aspect of this application and the products described in the second aspect of this application are applicable here and will not be repeated here.

[0051] Example

[0052] The present application will be more easily understood by referring to the following embodiments, which are only used to illustrate certain aspects and implementation methods of the present application and are not intended to limit the present application.

[0053] Unless otherwise stated, all materials used in this embodiment are commercially available or conventional materials.

[0054] Medium- and long-chain triglycerides (MLCT): Medium- and long-chain fatty acid edible oil purchased from Yihai Kerry Food Industries Co., Ltd. was used, in which the purity of MLCT was 61±10% (by mass) and the production batch number was 20250804. Osteopontin (OPN): Purchased from Arla, product number LACPRODAN® OPN-10, purity: 78.32%; Loratadine: purchased from Peking University Medicine Co., Ltd., tablets, batch number 241203; 1-Chloro-2,4-Dinitrobenzene (DNCB): Purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., batch number F2518064; Wild-type AB strain zebrafish: bred and provided by the fish breeding center of Hangzhou Huante Biotechnology Co., Ltd.

[0055] Example 1. Maximum tolerable concentration of a single sample

[0056] Wild-type AB strain zebrafish, 4 days post-fertilization (4 dpf), were randomly selected and enclosed in 6-well plates (3 mL per well). Thirty zebrafish were treated in each well, with three replicates per group. Each experiment included a normal control group, a model control group, a positive control group, and a single-sample group. Except for the normal control group, all other groups received water-soluble DNCB and were treated at 28°C for 21 h to establish a zebrafish eczema model. Subsequently, the positive control group received water-soluble loratadine at 187.5 ng / mL; the single-sample groups received water-soluble MLCT or OPN at specified concentrations. The concentrations used in the single-sample groups are shown in Table 1 below. After a further 3 h of treatment at 28°C, the maximum tolerated concentration (MTC) of the single sample against the model zebrafish was determined.

[0057] Table 1. Experimental results of maximum detectable concentration for a single sample (n = 30)

[0058]

[0059] As shown in Table 1, the MTC of medium- and long-chain triglycerides was 2000 μg / mL, and the MTC of osteopontin was 500 μg / mL.

[0060] Example 2. Efficacy of the Sample in Improving Eczema – Behavioral (Pruritus) Efficacy Evaluation

[0061] Wild-type AB strain zebrafish with a dpf of 4 were randomly selected and placed in 6-well plates with a volume of 3 mL per well. Thirty zebrafish were treated, and each group was set up in triplicate. Each experiment included a normal control group, a model control group, a positive control group, a single-sample control group (MLCT: comparative examples 1 to 3; OPN: comparative examples 4 to 6), and an experimental group (formulas 1 to 7). Except for the normal control group, all other groups were given DNCB in water and treated at 28°C for 21 h to establish a zebrafish eczema model. Subsequently, the positive control group was given loratadine in water at 187.5 ng / mL; the single-sample control group was given MLCT or OPN at a specified concentration in water; and the experimental group was given MLCT + OPN at a specified concentration in water. The concentrations used in the single-sample control group and the experimental group are shown in Table 2 below. After a further 3 h of treatment at 28°C, 10 zebrafish from each group were randomly selected and placed in a 96-well plate, 1 zebrafish / well, 200 μL / well. Behavioral data for each group were collected over 20 minutes using a behavior analyzer (Zebra Lab 3.22.3.31, Viewpoint, France). The total movement distance of the zebrafish was measured, and the statistical analysis results of the above indicators were used to evaluate the efficacy of the samples in relieving itching, thereby characterizing the efficacy of the samples in improving eczema. Statistical results are expressed as mean ± standard error (SE) (n = 10). Statistical analysis was performed using SPSS software. P < 0.05 indicates that the difference is statistically significant.

[0062] In Table 2, the parameters are as follows: Total movement distance = The total distance the zebrafish moves in 20 minutes, in millimeters (mm); Recovery amount = Total movement distance of zebrafish in the model control group – Total movement distance of zebrafish in the single sample control group or experimental group, in mm; Synergistic recovery amount = Recovery amount of the experimental group – Sum of recovery amounts of the corresponding concentration of the single-sample control group, in mm; Synergy coefficient = Recovery amount of the experimental group / Sum of recovery amounts of the corresponding concentration of the single-sample control group; Unit dose synergy coefficient = synergy coefficient / sum of MLCT and OPN doses.

[0063] The results are shown in Table 2 and Figure 1 As shown.

[0064] Table 2. Results of the experiment evaluating the efficacy of the samples in improving eczema (behavioral (pruritus)).

[0065] Note: P <0.05, P <0.01, P <0.01

[0066] From Table 2 and Figure 1 The results showed that, compared with the normal control group, the total movement distance (mm) of the model control group was significantly increased, indicating that the zebrafish eczema model was successfully established by administering DNCB in water.

[0067] Compared with the model control group, the total movement distance of the positive control group given loratadine was significantly reduced (recovered), indicating that the pruritus symptoms of the zebrafish model were improved, and thus the eczema condition was improved.

[0068] Compared with the model control group, the single-sample control group given OPN alone showed varying degrees of reduction in total motor distance, indicating that OPN alone has the effect of improving eczema; however, the single-sample control group given MLCT alone did not show a significant reduction in total motor distance, indicating that MLCT alone does not have a significant effect of improving eczema.

[0069] Compared with the model control group, the total movement distance of the experimental groups using the combination of MLCT and OPN was significantly reduced (P<0.05). For example, the experimental groups given formulas 1 to 7 all showed a significant reduction in total movement distance, indicating that the combination of MLCT and OPN can significantly improve eczema.

[0070] Furthermore, compared to the single-sample control group, the combined use of MLCT and OPN showed a significant synergistic effect. For example, as shown in Table 2, the synergistic recovery amounts of formulation 1 (500 μg / mL MLCT + 100 μg / mL OPN), comparative example 1 (500 μg / mL MLCT), and comparative example 5 (100 μg / mL OPN) reduced the total motor distance by 592 mm, 201 mm, and 362 mm, respectively. The reduction in total motor distance caused by formulation 1 (592 mm) was greater than the sum of the reductions in motor distance caused by comparative examples 1 and 5 (563 mm), indicating a synergistic effect when MLCT and OPN are used in combination. Similarly, formulations 2 to 7 also showed a synergistic effect. Therefore, when MLCT and OPN are used in combination at a mass ratio ranging from 1:1 to 100:1, they show a synergistic effect in improving eczema.

[0071] On the other hand, synergistic effects can also be characterized by synergistic coefficients, where a synergistic coefficient greater than 1 indicates a synergistic effect. The calculated synergistic coefficient for formulation 1 is 1.0515 (>1), indicating a synergistic effect when MLCT and OPN are used together, synergistically reducing the total movement distance of the zebrafish model, thus demonstrating that the combination can synergistically improve eczema. Similarly, the synergistic coefficients for formulations 2 to 7 are also greater than 1, thus also showing a synergistic effect. This further indicates that when MLCT and OPN are used together in a mass ratio ranging from 1:1 to 100:1, they exhibit a synergistic effect in improving eczema. Furthermore, comparing the synergistic coefficients of each formulation, formulation 6 > formulation 7 > formulation 1 > formulation 4 > formulation 3 > formulation 5 > formulation 2, indicating that when the mass ratio of MLCT to OPN is in the range of 5:1 to 100:1 (with synergistic coefficients all greater than 1.02), it has a better synergistic effect in improving eczema (itching).

[0072] Furthermore, as shown in Table 2, formulations 1 to 7 also have satisfactory unit dose synergistic coefficients, indicating that when MLCT and OPN are used in combination at mass ratios within the above range, they have a good synergistic effect in improving eczema.

[0073] Example 3. Efficacy of the sample in improving eczema – Evaluation of efficacy in reducing trypsin levels

[0074] Wild-type AB strain zebrafish with a 4 dpf growth rate were randomly selected and placed in 6-well plates with a volume of 3 mL per well. Thirty zebrafish were treated, and each group was set up in triplicate. Each experiment included a normal control group, a model control group, a positive control group, a single-sample control group (MLCT: comparative examples 1 to 3; OPN: comparative examples 4 to 6), and an experimental group (formulas 1 to 7). Except for the normal control group, all other groups were given DNCB in water and treated at 28°C for 21 h to establish a zebrafish eczema model. Subsequently, the positive control group was given loratadine in water at 187.5 ng / mL; the single-sample control group was given MLCT or OPN at a specified concentration in water; and the experimental group was given MLCT + OPN at a specified concentration in water. The concentrations used in the single-sample control group and the experimental group are shown in Table 3 below. After continuing treatment at 28°C for 3 h, 10 zebrafish from each group were randomly selected and placed in a 96-well plate, 1 zebrafish / well, 200 μL / well.

[0075] The trypsin content in the model was detected using a trypsin assay kit (purchased from Shanghai Enzyme-Link Biotechnology Co., Ltd., catalog number ml286418V). Zebrafish samples were collected according to the instructions, and data were acquired using a multi-functional microplate reader (SPARK, TECAN, Austria) to analyze the trypsin content in the zebrafish model. Statistical analysis of this index was used to evaluate the efficacy of the sample in reducing trypsin content, thereby characterizing the efficacy of the sample in improving eczema. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software. P < 0.05 indicates that the difference is statistically significant.

[0076] In Table 3, the parameters are as follows: Trypsin content = Trypsin content in zebrafish model, in ng / mg prot; The reduction amount = trypsin content in zebrafish of the model control group – trypsin content in zebrafish of the single control or experimental group, in nanograms per milligram of protein (ng / mg prot). Synergistic reduction = Reduction in the experimental group – Sum of reductions in the corresponding concentration of the single-sample control group, in ng / mg prot; Synergy coefficient = (reduction in the experimental group / sum of reductions in the corresponding concentration of the single-sample control group); Unit dose synergy factor: synergy factor / sum of MLCT and OPN doses.

[0077] The results are shown in Table 3.

[0078] Table 3. Evaluation results of the samples' efficacy in improving eczema (trypsin content) (n = 10)

[0079] Note: P <0.05, P <0.01, P <0.01

[0080] As shown in Table 3, compared with the normal control group, the trypsin content in the model control group was significantly increased, indicating that the zebrafish eczema model was successfully established by administering DNCB in water.

[0081] Compared with the model control group, the trypsin content in the positive control group given loratadine was significantly reduced, indicating that the eczema condition in the zebrafish model was improved.

[0082] Compared with the model control group, the trypsin levels in the single-sample control group given OPN alone were reduced to varying degrees, indicating that OPN alone has the effect of improving eczema; however, the trypsin levels in the single-sample control group given MLCT alone were not significantly reduced, indicating that MLCT alone does not have a significant effect of improving eczema.

[0083] Compared with the model control group, the trypsin levels in the experimental groups using the combination of MLCT and OPN were significantly reduced (P<0.05). For example, the experimental groups given formulations 1 to 7 all showed a significant reduction in trypsin levels, indicating that the combination of MLCT and OPN can significantly improve eczema.

[0084] Furthermore, compared to the single-sample control group, the combined use of MLCT and OPN showed a significant synergistic effect. For example, as shown in Table 3, formulation 1 (500 μg / mL MLCT + 100 μg / mL OPN), Comparative Example 1 (500 μg / mL MLCT), and Comparative Example 5 (100 μg / mL OPN) reduced trypsin levels by 0.53 ng / mg prot, 0.08 ng / mg prot, and 0.18 ng / mg prot, respectively. The reduction in trypsin levels caused by formulation 1 (0.53 ng / mg prot) was greater than the sum of the reductions in trypsin levels caused by Comparative Example 1 and Comparative Example 5 (0.26 ng / mg prot), indicating a synergistic effect when MLCT and OPN are used in combination. Similarly, formulations 2 to 7 also showed a synergistic effect. Therefore, when MLCT and OPN are used in combination at a mass ratio ranging from 1:1 to 100:1, they show a synergistic effect in improving eczema.

[0085] On the other hand, synergistic effects can also be characterized by a synergistic coefficient, where a synergistic coefficient greater than 1 indicates a synergistic effect. The calculated synergistic coefficient for formulation 1 is 2.0090 (>1), indicating a significant synergistic effect when MLCT and OPN are used in combination, synergistically reducing trypsin levels in the zebrafish model, thus demonstrating that the combination can synergistically improve eczema. Similarly, the synergistic coefficients for formulations 2 to 7 are also greater than 1, thus also showing a synergistic effect. Therefore, it is further demonstrated that when MLCT and OPN are used in combination at a mass ratio ranging from 1:1 to 100:1, they exhibit a synergistic effect in improving eczema.

[0086] Furthermore, as shown in Table 3, formulations 1 to 7 also have satisfactory unit dose synergistic coefficients, indicating that when MLCT and OPN are used in combination at mass ratios within the above range, they have a good synergistic effect in improving eczema.

[0087] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of this application.

Claims

1. The use of the composition in the preparation of a product for improving eczema, characterized in that, The composition comprises: Medium- and long-chain fatty acid triglycerides, and osteopontin, The mass ratio of the medium- and long-chain fatty acid triglycerides to the osteopontin is 1:1 to 100:

1.

2. The use according to claim 1, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the osteopontin is 5:1 to 100:

1.

3. The use according to claim 1, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the osteopontin is 1:1 to 50:

1.

4. The use according to claim 1, characterized in that, The mass ratio of the medium- and long-chain fatty acid triglycerides to the osteopontin is 5:1 to 50:

1.

5. The use according to any one of claims 1 to 4, characterized in that, The eczema described is allergic eczema.

6. The use according to any one of claims 1 to 4, characterized in that, The improvement of eczema includes relieving itching and reducing trypsin levels, or one or more of these.

Images